Jubilant Pharmova , a prominent player in the pharmaceutical industry, has announced a significant move to strengthen its position in the Active Pharmaceutical Ingredients (API) market. The company's board has approved a strategic acquisition that involves a combination of share distribution and cash payment.

Key Details of the Acquisition

• Transaction Value: The total transaction value is set at ₹595.59 crore, comprising both share distribution and cash payment.
• Share Distribution: Jubilant Pharmova will distribute 5,15,59,030 Optionally Convertible Redeemable Preference Shares (OCRPS).
• OCRPS Value: The OCRPS are valued at ₹515.59 crore.
• Additional Cash Payment: The company will make an additional cash payment of ₹80.00 crore.
• Target Business: The acquisition targets the API business of Jubilant Biosys.

Strategic Implications

This move by Jubilant Pharmova signifies a strategic expansion of its API capabilities. The acquisition of Jubilant Biosys's API business is likely to enhance Jubilant Pharmova's product portfolio and manufacturing capabilities in the pharmaceutical ingredients sector.

Market Impact

The acquisition is expected to have a notable impact on Jubilant Pharmova's market position:

1. Vertical Integration: By bringing API production in-house, the company may achieve greater control over its supply chain.
2. Expanded Offerings: The addition of Jubilant Biosys's API business could potentially broaden Jubilant Pharmova's product range.
3. Competitive Edge: This move may strengthen Jubilant Pharmova's competitive position in the pharmaceutical market.

Financing Structure

The financing structure of this deal is noteworthy:

• The majority of the transaction (₹515.59 crore) is financed through the distribution of OCRPS.
• The remaining ₹80.00 crore will be paid in cash.

This structure suggests a strategic approach to financing that balances the company's cash position with equity-linked instruments.

The pharmaceutical sector continues to see consolidation and strategic acquisitions as companies aim to strengthen their market positions and expand their capabilities. Jubilant Pharmova's latest move aligns with this industry trend, potentially setting the stage for enhanced growth and competitiveness in the API market.

Jubilant Pharmova Limited , a prominent player in the pharmaceutical sector, has announced the appointment of Arun Kumar Sharma as its interim Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective October 1, 2025. This strategic move comes as the company continues its search for a permanent CFO.

Board Approval and Appointment Details

The Board of Directors of Jubilant Pharmova approved Sharma's appointment on September 23, 2025, following recommendations from the Nomination, Remuneration and Compensation Committee and the Audit Committee. The decision was made during a board meeting that commenced at 10:35 a.m. and concluded at 11:20 a.m.

Transition Period and Role

Sharma's appointment is designed to ensure a smooth transition while the company progresses with its process to identify and appoint a permanent CFO. He will hold the position of CFO for an interim period until a new permanent CFO is appointed.

Arun Kumar Sharma's Extensive Experience

With over three decades of experience in the financial sector, Arun Kumar Sharma brings a wealth of knowledge to his new role at Jubilant Pharmova. His expertise spans various critical areas, including:

• Corporate finance
• Global treasury
• Investor relations
• Risk management
• Financial restructuring
• Insurance
• Capital expenditure control
• Business transformation

Previous Roles within Jubilant Bhartia Group

Sharma's appointment marks a return to the Jubilant family, as he has previously held several key positions within the Jubilant Bhartia Group:

• CFO at Jubilant Pharma Holdings Inc. USA for approximately 4 years
• CFO at Jubilant Lifesciences Limited (Chemical Business) for approximately 3 years
• CFO at Jubilant Pharmova Limited for approximately 2 years (April 2021 to May 2023)

Leadership and Value Creation

Throughout his career, Sharma has demonstrated excellence in driving sustainable growth, enhancing shareholder value, and upholding governance standards in large listed companies. His strategic and result-driven approach aligns well with Jubilant Pharmova's objectives.

Regulatory Compliance

The appointment of Arun Kumar Sharma complies with Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements Regulations, 2015. The company has duly informed the stock exchanges, BSE Limited and the National Stock Exchange of India Limited, about this significant development.

Jubilant Pharmova's decision to bring Arun Kumar Sharma on board as interim CFO reflects the company's commitment to maintaining strong financial leadership during its search for a permanent CFO. Sharma's extensive experience within the Jubilant Group and his proven track record in financial management position him well to guide the company's financial strategies in the interim period.